Crinetics Pharmaceuticals, Inc. Current Assets
Crinetics Pharmaceuticals, Inc. (CRNX) had Current Assets of $1.24 billion as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-03
- 2026-06-30: Assets, Current $1.24B.
- 2026-03-31: Assets, Current $1.32B.
- 2025-12-31: Assets, Current $1.05B.
- 2025-09-30: Assets, Current $1.12B.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $1.24B 10-Q · filed 2026-08-03 |
| 2026-03-31 | $1.32B 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.05B 10-Q · filed 2026-08-03 |
| 2025-09-30 | $1.12B 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.22B 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.29B 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.38B 10-K · filed 2026-02-26 |
| 2024-09-30 | $877.59M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $874.78M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $917.23M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $574.15M 10-K · filed 2025-02-27 |
| 2023-09-30 | $575.76M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $284.81M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $305.40M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $345.18M 10-K · filed 2024-02-28 |
| 2022-09-30 | $378.32M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $416.29M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $328.25M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $344.72M 10-K · filed 2023-02-28 |
| 2021-09-30 | $203.97M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $211.35M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $157.80M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $177.49M 10-K · filed 2022-03-30 |
| 2020-09-30 | $194.12M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $210.61M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $117.17M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $123.34M 10-K · filed 2021-03-30 |
| 2019-09-30 | $135.40M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $147.76M 10-Q · filed 2019-08-13 |
| 2019-03-31 | $159.12M 10-Q · filed 2019-05-13 |
| 2018-12-31 | $166.68M 10-K · filed 2020-03-09 |
| 2018-09-30 | $171.04M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $69.94M 10-Q · filed 2018-08-30 |
| 2017-12-31 | $15.16M 10-K · filed 2019-03-13 |